SS-31: mechanism, evidence and a specific approval AXON Research Institute | Original silent educational pilot 5 November 2026 Educational draft. Scientific and legal review pending. No audio. Burned-in captions. Original conceptual diagrams. No medical advice. AXON Research Institute is affiliated with AXON Peptide. COMPOUND FIELD NOTES / 001 SS-31, also called elamipretide, is a four-amino-acid peptide studied for its effects on mitochondria. Its story shows why a promising mechanism, an animal experiment, and a human treatment claim are different kinds of evidence. 01 / MOLECULAR RATIONALE The central target is cardiolipin, a lipid in the inner mitochondrial membrane. Laboratory experiments found that SS-31 interacts with cardiolipin and can limit the damaging peroxidase activity of cytochrome c, a protein that normally helps transfer electrons. [1][2][5] 02 / LABORATORY EVIDENCE Related experiments in isolated mitochondria found improvements in electron transport and ATP production. These findings explain a biological rationale. They do not establish a general energy boost in people. [1][2] 03 / ANIMAL EVIDENCE In a rat model of interrupted blood flow to the kidneys, pretreatment with SS-31 preserved mitochondrial membrane folds and supported recovery after blood flow returned. That is evidence from a particular injury model, not proof of human rejuvenation or longer life. [1] 04 / RANDOMIZED HUMAN EVIDENCE In MMPOWER-3, a randomized trial involving 218 participants with primary mitochondrial myopathy, elamipretide did not significantly improve six-minute walking distance or fatigue compared with placebo after 24 weeks. Exploratory findings should not replace that overall result. [3] 05 / BARTH SYNDROME In Barth syndrome, a separate randomized crossover study of twelve participants also failed to show benefit on its primary walking and fatigue endpoints. Improvements were subsequently observed during an open-label extension, when participants knew they were receiving treatment and there was no concurrent placebo group. Those design differences matter. [4] 06 / U.S. REGULATORY STATUS In September 2025, the FDA granted accelerated approval to Forzinity, the prescription elamipretide product, to improve muscle strength in adults and children with Barth syndrome weighing at least thirty kilograms. This approval is specific to the product, condition, and eligible population. [5][6] 07 / WHAT STILL NEEDS CONFIRMATION The approval relied on improved knee-extensor strength as an intermediate clinical endpoint. A confirmatory trial is required to establish that this translates into patient benefit. It does not establish an anti-aging treatment or a general performance enhancer. [5][6] 08 / SAFETY AND PRODUCT CONTEXT Injection-site reactions are common, and serious allergic reactions have been reported. A research-use label on a vial does not make it the FDA-approved product. This overview is education, not a recommendation to use a compound. [5] 09 / THE AXON READING FRAMEWORK The key takeaway: identify the model, examine the endpoint, and keep the claim within the evidence. This original AXON educational draft uses on-screen captions and conceptual diagrams. Scientific and legal review are pending. The transcript and linked sources accompany the video. [1][2][3][4][5][6] SOURCES [1] Birk et al. · JASN · 2013 https://pubmed.ncbi.nlm.nih.gov/23813215/ Cardiolipin mechanism and rat renal ischemia model. [2] Birk et al. · British Journal of Pharmacology · 2014 https://pmc.ncbi.nlm.nih.gov/articles/PMC3976619/ Experiments in model membranes and isolated mitochondria. [3] Karaa et al. · MMPOWER-3 · Neurology · 2023 https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/ Randomized trial in primary mitochondrial myopathy; 218 participants. [4] Thompson et al. · Genetics in Medicine · 2021 https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/ Barth syndrome randomized crossover trial and open-label extension. [5] FDA · Forzinity prescribing information · 2025 https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf Approved indication, accelerated approval, warnings, clinical studies. [6] FDA · Approval announcement · 19 September 2025 https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome Specific approval and required confirmatory study.